These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8750153)

  • 1. Bcl-2 protein expression in breast cancer in relation to established prognostic factors and other clinicopathological variables.
    Binder C; Marx D; Overhoff R; Binder L; Schauer A; Hiddemann W
    Ann Oncol; 1995 Dec; 6(10):1005-10. PubMed ID: 8750153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.
    Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO
    Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas.
    Luna-Moré S; de los Santos F; Bretón JJ; Cañadas MA
    Pathol Res Pract; 1996 Jan; 192(1):27-32. PubMed ID: 8685038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status.
    Doglioni C; Dei Tos AP; Laurino L; Chiarelli C; Barbareschi M; Viale G
    Virchows Arch; 1994; 424(1):47-51. PubMed ID: 7981903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity.
    Bhargava V; Kell DL; van de Rijn M; Warnke RA
    Am J Pathol; 1994 Sep; 145(3):535-40. PubMed ID: 8080038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy.
    Gee JM; Robertson JF; Ellis IO; Willsher P; McClelland RA; Hoyle HB; Kyme SR; Finlay P; Blamey RW; Nicholson RI
    Int J Cancer; 1994 Dec; 59(5):619-28. PubMed ID: 7960234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.
    Ioachim EE; Malamou-Mitsi V; Kamina SA; Goussia AC; Agnantis NJ
    Anticancer Res; 2000; 20(6B):4221-5. PubMed ID: 11205251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer.
    Binder C; Marx D; Binder L; Schauer A; Hiddemann W
    Ann Oncol; 1996 Feb; 7(2):129-33. PubMed ID: 8777167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
    Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
    Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial UCP4 and bcl-2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors.
    Gonidi M; Athanassiadou AM; Patsouris E; Tsipis A; Dimopoulos S; Kyriakidou V; Chelidonis G; Athanassiadou P
    Pathol Res Pract; 2011 Jun; 207(6):377-82. PubMed ID: 21621926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.
    Watanabe T; Fukutomi T; Tsuda H; Adachi I; Nanasawa T; Yamamoto H; Abe K
    Jpn J Cancer Res; 1993 Dec; 84(12):1279-86. PubMed ID: 7904987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.
    Schönborn I; Zschiesche W; Spitzer E; Minguillon C; Möhner M; Ebeling K; Grosse R
    Breast Cancer Res Treat; 1994; 29(3):287-95. PubMed ID: 7914107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 expression is associated with lymph node metastasis in human ductal breast carcinoma.
    Sierra A; Lloveras B; Castellsagué X; Moreno L; García-Ramirez M; Fabra A
    Int J Cancer; 1995 Jan; 60(1):54-60. PubMed ID: 7814152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer.
    Zschiesche W; Schönborn I; Minguillon C; Spitzer E
    Cancer Lett; 1994 Jun; 81(1):89-94. PubMed ID: 7912648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.
    Gasparini G; Gullick WJ; Maluta S; Dalla Palma P; Caffo O; Leonardi E; Boracchi P; Pozza F; Lemoine NR; Bevilacqua P
    Eur J Cancer; 1994; 30A(1):16-22. PubMed ID: 7908213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
    Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
    Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
    [No Abstract]   [Full Text] [Related]  

  • 19. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
    Silvestrini R; Veneroni S; Daidone MG; Benini E; Boracchi P; Mezzetti M; Di Fronzo G; Rilke F; Veronesi U
    J Natl Cancer Inst; 1994 Apr; 86(7):499-504. PubMed ID: 8133533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group.
    Nathan B; Gusterson B; Jadayel D; O'Hare M; Anbazhagan R; Jayatilake H; Ebbs S; Micklem K; Price K; Gelber R
    Ann Oncol; 1994 May; 5(5):409-14. PubMed ID: 7915536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.